anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: RARS2-related mitochondrial disorder is an autosomal recessive mitochondrial encephalopathy caused by biallelic pathogenic variants in the gene encoding the mitochondrial arginyl-transfer RNA synthetase 2 (RARS2, MIM *611524, NM_020320.5). RARS2 catalyzes the transfer of L-arginine to its cognate tRNA during the translation of mitochondrially-encoded proteins. The classical presentation of RARS2-related mitochondrial disorder includes pontocerebellar hypoplasia (PCH), progressive microcephaly, profound developmental delay, feeding difficulties, and hypotonia. Most patients also develop severe epilepsy by three months of age, which consists of focal or generalized seizures that frequently become pharmacoresistant and lead to developmental and epileptic encephalopathy (DEE).
CASE PRESENTATION: Here, we describe a six-year-old boy with developmental delay, hypotonia, and failure to thrive who developed an early-onset DEE consistent with Lennox-Gastaut Syndrome (LGS), which has not previously been observed in this disorder. He had dysmorphic features including bilateral macrotia, overriding second toes, a depressed nasal bridge, retrognathia, and downslanting palpebral fissures, and he did not demonstrate progressive microcephaly. Whole genome sequencing identified two variants in RARS2, c.36 + 1G > T, a previously unpublished variant that is predicted to affect splicing and is, therefore, likely pathogenic and c.419 T > G (p.Phe140Cys), a known pathogenic variant. He exhibited significant, progressive generalized brain atrophy and ex vacuo dilation of the supratentorial ventricular system on brain MRI and did not demonstrate PCH. Treatment with a ketogenic diet (KD) reduced seizure frequency and enabled him to make developmental progress. Plasma untargeted metabolomics analysis showed increased levels of lysophospholipid and sphingomyelin-related metabolites.
CONCLUSIONS: Our work expands the clinical spectrum of RARS2-related mitochondrial disorder, demonstrating that patients can present with dysmorphic features and an absence of progressive microcephaly, which can help guide the diagnosis of this condition. Our case highlights the importance of appropriate seizure phenotyping in this condition and indicates that patients can develop LGS, for which a KD may be a viable therapeutic option. Our work further suggests that analytes of phospholipid metabolism may serve as biomarkers of mitochondrial dysfunction.
Cancer represents a major global public health burden, with new cases estimated to increase from 14 million in 2012 to 24 million by 2035. Primary prevention is an effective strategy to reduce the costs associated with cancer burden. For example, measures to ban tobacco consumption have dramatically decreased lung cancer incidence and vaccination against human papillomavirus can prevent cervical cancer development. Unfortunately, the etiological factors of many cancer types are not completely clear or are difficult to actively control; therefore, the primary prevention of such cancers is not practical. In this review, we update the progress on precision therapy by targeting the whole carcinogenesis process, especially for three high-risk groups: (1) those with chronic inflammation, (2) those with inherited germline mutations, and (3) those with precancerous lesions like polyps, gastritis, actinic keratosis or dysplasia. We believe that attenuating chronic inflammation, treating precancerous lesions, and removing high-risk tissues harboring germline mutations are precision methods for cancer prevention.
Colored medical water in a bath tub. A single 20 minutes-long treatment will be performed.
All CMHCs involved in the CBT+/EBP Initiative receive virtual clinician training, CBT-phone consultation options over 6-months, access to a supervisor monthly call, listservs (one supervisor-focused), and a yearly advanced clinical training and supervisor training. The Initiative is a program that has been ongoing since 2009.
Myopia constitutes a major threat to personal health globally for its increased prevalence. Moreover, its dose-related association with irreversible blindness complications such as myopic macular degeneration has been demonstrated. It is crucial to look for effective ways to control myopia in children to reduce risk of myopic pathologies in later life. Repeated low-level red-light (RLRL) therapy is an innovative and non-invasive therapeutic treatment for a variety of eye diseases. A previous randomized clinical trial suggested that RLRL could effectively controlled myopia progression without clinically observable side effects.

The purpose of this study is to evaluate the effect of RLRL on the retinal function and structure among myopic teenagers aged 15-16 years. The RLRL therapy will be carried out at school under supervision of the parents according to a standard protocol for the first month and then will be discontinued for 1 month. Detailed functional and structural examinations, including full field electroretinogram, multifocal electroretinogram, microperimetry, visual acuity, intraocular pressure, optical coherence tomography, optical coherence tomography angiography, cycloplegic spherical equivalent refraction, and biological parameters will be evaluated at 1 month, 2 months after enrollment.
This retrospective study is done in Ordu university Hospital among patients who administered to urology polyclinic between April 2013 and April 2014. Sexually active 102 patients whose blood types were known were included in this study. While 56 patients had sexual intercourse problems 46 had not and this group was taken as a control group. Individuals who had a sexual partner and whose sexual intercourse were continuing unproblematic ally were accepted as normal. Individuals who had not have sexual intercourse though having a sexual partner or unable to maintain the intercourse were accepted to have sexual dysfunction. Patients' sexual function was evaluated via the İEFF-5 questioning form. In the same session the patients' blood types were also recorded and their İEFF-5 (Erectile Function International Evaluation Form) symptom scores were compared with their blood types.
The invention provides a traditional Chinese medicine composition with mosquito repelling and itching relieving efficacies, and a preparation method thereof. The composition is prepared from raw medicines of, by weight: 30 to 50 parts of salvia miltiorrhiza, 15 to 25 parts of clove, 15 to 25 parts of radix astragali mongolici, 15 to 25 parts of honeysuckle flower, and 6 to 10 parts of wild dendranthema flower. According to the method provided by the present invention for preparing a Chinese herbal medicine extract, the extraction and separation method is simple, extraction rate of active components through ultrasonic and backflow extractions is high, product purity is high, and product quality is greatly improved. The traditional Chinese medicine components have functions of bacteria inhibiting, virus resisting, inflammation resisting, heat relieving, pain relieving, immune function regulating, sweat secretion inhibiting, skin soothing, and the like. Therefore, the extract have good efficacies as a mosquito repellant. The extract is widely applied in the preparation of ideal mosquito repelling floral water. As a result of experiments, the preparation has no toxic or side-effect, and is suitable for infants and children.
Obesity and its associated comorbid conditions have been increasing globally. Endoscopic bariatric and metabolic therapies (EBMTs) were initially designed to replicate bariatric surgery physiology for those who are not or choose not to be surgical candidates. Now, newer procedures target the complicated pathophysiology underlying obesity and its comorbidities. EBMT has been categorized based on its therapeutic target (stomach or small intestine), but innovations have expanded to include extraintestinal organs including the pancreas. Gastric EBMTs, namely space-occupying balloons, gastroplasty with suturing or plication, and aspiration therapy, are primarily used for weight loss. Small bowel EBMTs are designed to cause malabsorption, epithelial endocrine remodeling, and other changes to intestinal physiology to ultimately improve the metabolic comorbidities of obesity rather than induce weight loss alone. These include duodenal mucosal resurfacing, endoluminal bypass sleeves, and incisionless anastomosis systems. Extraluminal or pancreatic EBMT is aimed to restore the production of normal pancreatic proteins that are involved in the progression of type 2 diabetes. This review discusses the current and new technologies of metabolic bariatric endoscopy, their pros and cons, and areas for future research.
Opioid administration is particularly challenging in the perioperative period. Computerized-based Clinical Decision Support Systems (CDSS) are a promising innovation that might improve perioperative pain control. We report the development and feasibility validation of a knowledge-based CDSS aiming at optimizing the management of perioperative pain, postoperative nausea and vomiting (PONV), and laxative medications. This novel CDSS uses patient adaptive testing through a smartphone display, literature-based rules, and individual medical prescriptions to produce direct medical advice for the patient user. Our objective was to test the feasibility of the clinical use of our CDSS in the perioperative setting. This was a prospective single arm, single center, cohort study conducted in Strasbourg University Hospital. The primary outcome was the agreement between the recommendation provided by the experimental device and the recommendation provided by study personnel who interpreted the same care algorithm (control). Thirty-seven patients were included in the study of which 30 (81%) used the experimental device. Agreement between these two care recommendations (computer driven vs. clinician driven) was observed in 51 out 54 uses of the device (94.2% [95% CI 85.9-98.4%]). The agreement level had a probability of 86.6% to exceed the 90% clinically relevant agreement threshold. The knowledge-based, patient CDSS we developed was feasible at providing recommendations for the treatment of pain, PONV and constipation in a perioperative clinical setting.Trial registration number & date The study protocol was registered in ClinicalTrial.gov before enrollment began (NCT05707247 on January 26th, 2023).
FIELD: chemical engineering. SUBSTANCE: method involves using ferromagnetic or ferromagnetic colloid particles as identifiable magnetic markers in immune methods and other binding methods for qualitatively and/or quantitatively detecting analyte presence in liquid and/or solid phases. Magnetization relaxation of the particles is treated as a value to be measured. Relaxation according to method after Broun is accomplished quicker as that according to method after Neel. Immunomagnetography is carried out by labeling substances with ferromagnetic or ferromagnetic colloid particles. Labeled substances having specified structure are introduced into living organism. Spatial area under study in organism is magnetized using magnetic field applied from outside. Magnetic relaxation of magnetic markers is measured using magnetic field sensory units after switching off the external field. EFFECT: high sensitivity in detecting analyte presence. 29 cl, 4 dwg
PURPOSE: A flavonoid compound derived from Vitex rotundifolia is provided to reduce Bcl-2 expression in cancer cells and to induce cancer cell apoptosis. CONSTITUTION: A pharmaceutical composition for preventing and treating cancer contains Vitex rotundifolia extract as an active ingredient. The extract is isolated using methylene chloride or methanol. The extract is also H_2O, n-BuOH, 85% aq. MeOH, or n-hexane fraction. A pharmaceutical composition for preventing or treating cancer contains flavonoid compounds of chemical formula 1 derived from Vitex rotundifolia or pharmaceutically acceptable salt thereof as an active ingredient. The cancer is gastric cancer, fibrosarcoma, or breast cancer. A health food composition for preventing or treating cancer contains Vitex rotundifolia extract as an active ingredient.
PURPOSE:To provide a highly safe cosmetic composition having an excellent touch by containing a Hippophae rhamnoides. L oil fatty acid ester prepared by esterifying the Hippophae rhamnoides. L oil fatty acid or a hydrogenated product thereof or by subjecting the Hippophae rhamnoides. L oil to an ester exchange reaction. CONSTITUTION:Hippophae rhamnoides. L oil containing palmitoleic acid in a high concentration but having been compounded with cosmetics in limited amounts because of having a strong orange color and a characteristic odor is hydrolyzed and the prepared Hippophae rhamnoides. L fatty acid or a hydrogenated product thereof is subsequently esterified with a 1-27C straight chain or branched chain saturated or unsaturated alcohol having preferably 1-12 OH groups or the Hippophae rhamnoides. L oil or a hydrogenated product thereof is subjected to a direct ester exchange reaction to form a substantially tasteless and odorless Hippophae rhamnoides. L oil fatty acid ester. At least one kind of the Hippophae rhamnoides. L oil fatty acid ester is compounded with a cosmetic to provide a cosmetic composition to which the Hippophae rhamnoides. L can be added in a free amount and gives a better feeling to the skin than the Hippophae rhamnoides. L.
Hypoxia is an independent marker of a poor prognosis for subjects with metastatic melanoma (Simonetti 2012, Lartigau 1997). Hypoxic melanoma cells are more likely to exhibit a stem-cell like phenotype with an associated increased propensity for invasion, angiogenesis, and metastasis formation compared to normoxic cells. Moreover, this phenotype is also associated with treatment resistance. TH-302, a hypoxia activated prodrug (HAP), was designed to target the hypoxic nature of tumours while having a minimal effect on normoxic tissue. TH-302 belongs to a class of alkylating agents that have significant experimental and clinical activity (Brock 1989). Preclinical data support the hypothesis that TH-302 targets hypoxic regions of tumours and is also able to kill tumour cells in normoxic regions as a result of cytotoxin diffusion, leading to significant effects on tumour growth (Meng 2011). TH-302 has been investigated in over 700 subjects with solid tumours or hematologic malignancies, including subjects with metastatic melanoma. In this subset a disease control rate of 63% (3 subjects with partial responses and 9 subjects with stable disease out of a total of 19) was observed in an early phase clinical trial of TH-302 (Weber 2010). Predictive biomarkers for response and toxicity have yet to be identified for subjects with advanced melanoma treated with TH-302. Optimal patient selection may be critical to maximize the clinical benefit. A predictive biomarker approach will be investigated to try to identify subjects most likely to benefit from TH-302. Given the hypoxia-targeting mechanism of TH- 302, it is believed that hypoxia biomarkers will be the most informative for identifying subjects likely to benefit from TH- 302; however, additional biomarkers including DNA repair biomarkers will also be investigated. In addition, this approach will also have potential to synergise with future immunotherapeutic approaches as suppressive T regulatory cells are thought to reside within hypoxic niches within the tumour microenvironment that would be amenable to targeting by TH-302.
The present invention includes the cloning of a novel human C.alpha. isoform , identified as the human C.alpha.-s protein on the basis of its similarity to  a recently characterized C.alpha. isoform which was identified by purification  and peptide sequencing of C.alpha. from ovine sperm [11]. The human C.alpha. -s protein was present in testis and ejaculated sperm and C.alpha.-s localized to the midpiece of human sperm. The present invention includes in this respect a cDNA sequence encoding a C.alpha.-s protein and comprises the specific nucleotide sequence shown in SEQ ID NO:1, (underlined) wherein the said protein is a new splice variant of C.alpha. catalytic subunit of cAMP dependent protein kinase. The present invention is further directed to a vector comprising the said cDNA sequence. The invention also includes a protein characterised by the C.alpha.-s protein specific amino acid sequence  shown in SEQ ID NO:2 (underlined). The invention includes further use of C.alpha.-s protein and cDNA sequence in preparation of pharmaceuticals, medicaments to manipulate the motility in sperm or for use as contraceptive,  as well as methods and testsystems for screening molecules interacting with C.alpha.-s. The present invention includes also a kit.
A traditional Chinese medicine for treating facial paralysis and prosopodynia is characterized by mainly comprising traditional Chinese medicines of 10 g of prepared radix aconiti, 10 g of prepared rhizoma typhonii, 10 g of rhizoma gastrodiae, 10 g of safflower, 10 g of prepared rhizoma arisaematis, 10 g of costustoot and the like. The preparation method comprises the following steps: decocting the above Chinese medicinal materials in water for 1 day for 3 times, and taking after meal. Decocting radix Aconiti Preparata, rhizoma Typhonii Preparata, and rhizoma arisaematis Preparata for 1 hr, and adding other medicinal materials after the medicinal liquid is not numb, and decocting for 10 min. One dose is taken every day. Five doses are taken as one treatment course. The prescription is prepared from pure Chinese medicaments by a traditional preparation method, retains the property of the medicaments, has the efficacies of expelling wind and removing cold, clearing and activating the channels and collaterals, and removing cold and relieving pain, achieves the aim of treatment and has no side effect.
Sodium Phosphates Injection, USP, 3 mM P/mL must be diluted and thoroughly mixed before use.

     To avoid phosphorus intoxication, infuse solutions containing sodium phosphate slowly. Infusing high concentrations of phosphorus may result in a reduction of serum calcium and symptoms of hypocalcemic tetany. Calcium levels should be monitored.
     Solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention.
     In patients with diminished renal function, administration of solutions containing sodium ions may result in sodium retention.
     WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.
     Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
OBJECTIVES: I. Assess the effects of amifostine on the response to remission induction therapy and consolidation with cytarabine and mitoxantrone in patients with poor prognosis acute myeloid leukemia (AML), relapsed AML, and blastic phase chronic myelogenous leukemia (CML). II. Assess the effects of amifostine on the biology of AML and CML cells in vivo in this patient population.

OUTLINE: Patients receive treatment prior to induction therapy on protocols CYL 90-03 and CYL 97-59. Induction therapy consists of amifostine IV on days 1 and 5 and three times a week from days 6 to 28. Fifteen minutes after amifostine on days 1 and 5, patients receive cytarabine IV over 3 hours at hour 0 and hour 12 and mitoxantrone IV over 1 hour at hour 15. Patients who do not enter remission receive a second course of induction therapy. Patients with persistent AML following a second course are removed from the study. Patients who achieve a complete response (CR), clinical CR, or remission in bone marrow but without hematologic recovery or who return to myelodysplastic syndrome receive consolidation therapy. Consolidation therapy consists of amifostine IV on days 1 and 5 and then three times a week until blood counts recover or day 30, whichever comes first. Patients also receive cytarabine and mitoxantrone as in induction therapy. Patients receive a second course of consolidation therapy beginning 1 week after blood counts recover. After completion of consolidation therapy, patients are enrolled on protocol MDS 97-53.

PROJECTED ACCRUAL: A maximum of 50 patients will be accrued for this study.
Participants will receive alectinib treatment continuously starting from Day 1 Cycle 1 (in 28-day cycles) until disease progression, death, or withdrawal for any other reasons, whichever occurs first. After PD, participants without EGFR mutation will continue treatment with alectinib alone and participants with EGFR mutation will receive alectinib in combination with erlotinib as per discretion of the treating physician.
Polybrominated diphenyl ethers (PBDEs) are legacy flame retardants that bioaccumulate in the environment. The gut microbiome is an important regulator of liver functions including xenobiotic biotransformation and immune regulation. We recently showed that neonatal exposure to polybrominated diphenyl ether-99 (BDE-99), a human breast milk-enriched PBDE congener, up-regulated proinflammation-related and down-regulated drug metabolism-related genes predominantly in males in young adulthood. However, the persistence of this dysregulation into late adulthood, differential impact among hepatic cell types, and the involvement of the gut microbiome from neonatal BDE-99 exposure remain unknown. To address these knowledge gaps, male C57BL/6 mouse pups were orally exposed to corn oil (10 ml/kg) or BDE-99 (57 mg/kg) once daily from postnatal days 2-4. At 15 months of age, neonatal BDE-99 exposure down-regulated xenobiotic and lipid-metabolizing enzymes and up-regulated genes involved in microbial influx in hepatocytes. Neonatal BDE-99 exposure also increased the hepatic proportion of neutrophils and led to a predicted increase of macrophage migration inhibitory factor signaling. This was associated with decreased intestinal tight junction protein (Tjp) transcripts, altered gut environment, and dysregulation of inflammation-related metabolites. ScRNA-seq using germ-free (GF) mice demonstrated the necessity of a normal gut microbiome in maintaining hepatic immune tolerance. Microbiota transplant to GF mice using large intestinal microbiome from adults neonatally exposed to BDE-99 down-regulated Tjp transcripts and up-regulated several cytokines in large intestine. In conclusion, neonatal BDE-99 exposure reprogrammed cell type-specific gene expression and cell-cell communication in liver towards proinflammation, and this may be partly due to the dysregulated gut environment.
This invention provides methods and kits for maintaining pregnancy in mammals.  Pregnancy is maintained by administration of effective amounts of luteinizing hormone (LH) or chorionic gonadotropin (CG). Both LH and CG may be used alone, in combination with each other, or in combination with growth hormone (GH) or follicle stimulating hormone (FSH). Hormones are administered on about Day 4 to about Day 7 following insemination. Effective amounts of LH range from about 10 micrograms to about 25 milligrams, preferably about 2 to about 8 mg, and of CG range from about 100 IU (international units) to about 2000 IU.  Mammals treatable by the methods of this invention include ungulates and related mammals, including bovines. Kits provided by this invention include effective amounts of one or more hormones, a device for administering the hormone(s) and instructions. This invention also provides methods for treating follicular cysts and for synchronizing ovulation in mammals using LH.